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TCR chain gangs
 
T cell receptors (TCRs) band together to detect minute
amounts of antigen, according to Schamel and colleagues on
page 493. Their new work shows that TCRs are expressed on
the surface of resting T cells either individually or in groups. The
grouped TCRs, but not the solitary receptors, were triggered by
low dose antigen, suggesting that these receptors must cooperate
when antigen is scarce.
Whether TCRs exist as solitary entities or whether they group
together is a long-standing matter of debate. Previous studies have
failed to uncover evidence of grouped (multivalent) TCRs, but
this may have resulted from dismantling of the groups as a result
of overly harsh purification techniques.
In the new study, Schamel et al. gently coaxed the TCRs from
the cell membrane using a mild detergent, allowing the receptors to
retain both their native conformation and any associations with
neighboring membrane proteins. They discovered that up to 50%
of TCRs expressed by naive T cells associated with other TCRs
and formed linear multivalent chains on the cell surface.
Only the multivalent TCRs became phosphorylated in re-
sponse to low doses of antigen, which might explain how T
cells can detect and respond to rare antigenic peptide–MHC
T cell receptors are expressed either individually (red arrows) 
or as multivalent groups (black arrows). Only grouped TCRs 
respond to low-dose antigen.
 
complexes amidst a sea of self peptide–MHC pairs. The authors suggest that preexisting clusters of
TCRs may allow the responding TCR to facilitate phosphorylation of its neighbor, triggering a chain
reaction and making the most of an otherwise weak signal. The research teams are now looking for
multivalent TCRs on activated and memory T cells. They suspect that a higher proportion of multi-
valent TCRs on these cells might in part explain these cells’ increased responsiveness to antigen. 
 
Healing hearts and ﬁghting fat
 
Arresting intracellular hormone production helps keep arteries clear, according to a study on page 
517. Hermanowski-Vosatka and colleagues describe a novel chemical inhibitor that blocks the 
intracellular build up of the hormone cortisol, thereby preventing the development of 
atherosclerotic plaques in mice. This compound also alleviated multiple symptoms of a common 
disorder known as metabolic syndrome.
As the epidemics of obesity and type 2 diabetes grow, so does the incidence of metabolic 
syndrome—a disorder characterized by hypertension, insulin resistance, and visceral obesity. These 
symptoms add up to an elevated risk of atherosclerosis and coronary heart disease.
Although the etiology of metabolic syndrome remains obscure, increased intracellular levels of the 
glucocorticoid cortisol may be partly to blame. Cortisol is an adrenal hormone that regulates nutrient 
metabolism and inflammation. Recent studies in mice showed that overexpression of 11
 
 
 
-HSD1—the 
intracellular enzyme that converts inactive cortisone into active cortisol—leads to a disorder resembling 
metabolic syndrome, suggesting that an excess of intracellular cortisol may contribute to disease.
Although cardiovascular disease is the leading cause of mortality among patients with metabolic 
syndrome, a role for 11
 
 
 
-HSD1 in the development of cardiovascular symptoms had never been 
explored. Hermanowski-Vosatka et al. now describe a novel inhibitor of 11
 
 
 
-HSD1 that reduced the 
accumulation of plaque-forming cholesterol by nearly 90% in the aortas of mice. This inhibitor also 
protected mice from diet-induced obesity and type 2 diabetes, suggesting that deregulation of 
intracellular cortisol may be a unifying cause of the symptoms of metabolic syndrome.
The dramatic protection against plaque formation was associated with only modest reductions 
in serum lipids and glucose (known contributors to atherosclerotic plaque formation), suggesting 
that the inhibitor also affects other pathways. The authors suspect that the drug may suppress 
inflammation in vessels, which could help protect against atherosclerosis, as inflammation is 
associated with exacerbated cardiovascular disease in both mice and humans. 
Inhibition of the cortisol-producing 
enzyme 11 -HSD1 prevents the 
development of atherosclerosis and 
improves the symptoms of metabolic 
syndrome.
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XBP-1 image overhaul
 
The development of antibody-secreting plasma cells is crippled
in the absence of the transcription factor XBP-1 (X-box
binding protein). Based on the role of XBP-1 in the endo-
plasmic reticulum (ER) unfolded protein response (UPR),
it was speculated that the ER needs this protein to cope with
the ramped-up protein production that accompanies plasma
cell differentiation. On page 505, Tirosh and coworkers
show instead that XBP-1 controls immunoglobulin synthe-
sis posttranslationally, independently of its role in orches-
trating the UPR.
The UPR is a signaling system that ensures proper fold-
ing, processing, and degradation of proteins in the ER.
When protein production exceeds the ER’s quality control
capacity, XBP-1 drives the expression of additional proteins,
such as chaperones and degradative enzymes that help to
absorb the extra workload.
The prevailing explanation for the XBP-1 requirement
in plasma cell development—that the ER otherwise becomes
lethally clogged with excess immunoglobulin protein—is
called into question by the new data from Ploegh’s group.
The study shows that protein degradation in the ER was
intact in the absence of XBP-1, suggesting that the ER
quality control pathway in B cells does not require XBP-1.
Instead, XBP-1 was required for the sustained synthesis of
IgM in primary B cells. This defect was specific for IgM
heavy chain protein, as synthesis and trafficking of other
proteins were unaffected.
 
Water-clogging antibodies
 
Autoantibodies produced during a severe 
variant of multiple sclerosis (MS) latch on to 
water channels in the brain, according to 
Lennon and colleagues on page 473.
Optic–spinal MS (or neuromyelitis 
optica, NMO) is a severe demyelinating 
disease that affects the spinal cord and 
optic nerves and is often misdiagnosed as 
classical MS, despite the absence of typical 
MS-like brain lesions. This group recently 
described an antibody that was present in 
the serum of up to 70% of patients with 
NMO, but was never found in patients with 
classical MS. The antibody bound to an 
unidentified antigen prominent at the 
blood–brain barrier.
Lennon and her colleagues now 
identify the target of the antibody as 
the water channel aquaporin-4 (AQP4). 
AQP4 is the most abundant water 
channel in the brain and is concentrated 
in the astrocyte membranes that border 
 
Despite the drop in IgM protein production, IgM heavy
chain transcripts were not decreased in XBP-1–deficient
cells, suggesting that XBP-1 affected translation. Although
the mechanism is not yet clear, Ploegh suspects that XBP-1
might drive the expression of microRNAs that regulate
translation, similar to those that control gene expression during
neuronal development in worms and cell fate decisions in
developing hematopoietic cells. 
Electron micrograph of a mature plasma cell showing extensive 
endoplasmic reticulum.  Reproduced from Bosman et al. (1969. 
J. Exp. Med. 129:1029–1044).
 
the blood–brain barrier. The expression 
of this protein is increased in patients 
with epilepsy and certain brain tumors, 
probably accounting for the associated 
brain edema that can limit blood flow 
and deprive the brain of oxygen.
Lennon suspects that the 
consequences of the antibody’s binding to 
AQP4 in the brain are twofold. The binding 
might directly alter the function of the 
water channel, triggering swelling. The 
antibodies might also trigger complement 
activation, which could then initiate the 
robust inflammatory reaction that is 
characteristic of early NMO.
Aquaporins are also abundant in the 
kidney, where they are required for normal 
water retention and urine concentration. 
Indeed, the anti-AQP4 antibodies from the 
NMO patients reacted with kidney tissue. 
It remains a mystery why these patients do 
not develop renal abnormalities.
The authors now plan to test whether 
AQP4-specific antibodies can trigger an 
NMO-like disease in mice. In the meantime, 
they have shown that these antibodies 
provide a useful diagnostic tool to distinguish 
NMO patients from those with conventional 
MS, as the diseases call for distinct 
treatment strategies. 
Antibodies from patients with neuromyelitis 
optica bind to the water channel aquaporin-4 
(yellow) in brain tissue.
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